August 2021; 11 (4) Commentary
COVID-19 Vaccination in Patients With Multiple Sclerosis on Disease-Modifying Therapy
Andrew Wolf, Enrique Alvarez
First published April 14, 2021, DOI: https://doi.org/10.1212/CPJ.0000000000001088
Andrew Wolf
Department of Neurology, University of Colorado School of Medicine, Aurora.
Enrique Alvarez
Department of Neurology, University of Colorado School of Medicine, Aurora.
COVID-19 Vaccination in Patients With Multiple Sclerosis on Disease-Modifying Therapy
Andrew Wolf, Enrique Alvarez
Neurol Clin Pract Aug 2021, 11 (4) 358-361; DOI: 10.1212/CPJ.0000000000001088
Citation Manager Formats
Make Comment
See Comments

Article Figures & Data
Tables
The Nerve!: Rapid online correspondence
No comments have been published for this article.
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Advertisement
Dr. Jessica Ailani and Dr. Ailna Masters-Israilov
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Views & Reviews
Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 PandemicMartin S. Weber, Jacqueline A. Nicholas, Michael R. Yeaman et al.Neurology: Neuroimmunology & Neuroinflammation, September 08, 2021 -
Article
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosisThe VELOCE studyAmit Bar-Or, Jonathan C. Calkwood, Cathy Chognot et al.Neurology, July 29, 2020 -
Research
Uptake and Attitudes About Immunizations in People With Multiple SclerosisRuth Ann Marrie, Leanne Kosowan, Gary R. Cutter et al.Neurology: Clinical Practice, April 22, 2021 -
Article
Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosisLudwig Kappos, Matthias Mehling, Rafael Arroyo et al.Neurology, January 30, 2015